Boston Scientific nets Farapulse approval, pushes back US TAVR launch

The device maker disclosed it will start the highly anticipated launch of the AFib ablation device, but approval for its aortic valve replacement implant will have to wait. 

By Susan Kelly • Jan. 31, 2024

The top medtech trends in 2024

Experts said M&A, orthopedic procedure backlogs and emerging cardiac markets were among the top trends to watch in the medical device industry this year.

By MedTech Dive Staff • Jan. 31, 2024

What to watch for as Stryker, Boston Scientific and BD post earnings this week

The next round of results follows reports from J&J, Abbott and Intuitive, all of which signaled a solid end to 2023.

By Nick Paul Taylor • Jan. 29, 2024

Robot reveal: Intuitive submits 510(k) for next-generation system

The new surgical robot will have 10,000 times the processing power of the current da Vinci model, CEO Gary Guthart said on the company’s fourth-quarter earnings call.

By Susan Kelly • Jan. 24, 2024

Abbott says all four segments stronger than pre-pandemic

CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”

By Elise Reuter • Jan. 24, 2024

3M on track to complete healthcare spinoff in first half of 2024

The healthcare leadership team will share more details as the completion of the transaction approaches.

By Nick Paul Taylor • Jan. 24, 2024

J&J expects strong procedure volumes in 2024

After reporting growth for its procedure-based units in the fourth quarter, J&J forecast surgery volumes to be above pre-pandemic levels this year.

By Ricky Zipp • Jan. 23, 2024

3 bellwether companies to watch as medtech earnings season begins

J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.

By Nick Paul Taylor • Jan. 22, 2024

Intuitive CEO: Strong robot placements offset bariatric surgery slowdown

Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries.

By Susan Kelly • Jan. 11, 2024

Masimo’s preliminary Q4 results, 2024 outlook exceed analyst expectations

Analysts see the update as evidence Masimo may be rebounding after failing to meet their expectations earlier in the year.

By Nick Paul Taylor • Jan. 11, 2024

5 medtech trends to watch in 2024

From the M&A outlook and tough year-over-year comparisons to emerging markets like pulsed field ablation, here are the top medical technology trends to watch this year.

By Ricky Zipp • Jan. 9, 2024

Edwards to spin off its critical care business

Edwards is the latest healthcare firm to spin off a business to focus on specific markets, following larger companies like Johnson & Johnson and GE.

By Ricky Zipp • Dec. 8, 2023

Roundup: Top medtech companies cut jobs in 2023

Johnson & Johnson, Medtronic and Abbott were among the top companies to announce layoffs this year as the industry implemented cost-cutting measures.

By Ricky Zipp • Nov. 27, 2023

Medtronic CEO downplays the impact of obesity drugs on bariatric surgeries, diabetes unit

The company is the latest medtech to address concerns about how weight loss drugs may impact growth.

By Ricky Zipp • Nov. 21, 2023

Q3 recap: Medtech firms grapple with layoffs, GLP-1s and China slowdown

Despite these challenges, companies also flagged improvements in supply chain dynamics and pricing that could boost their earnings.

By Elise Reuter • Updated Nov. 21, 2023

Illumina explores options for Grail, hires advisers

The company, facing pressure from regulators to divest Grail, also formed a special committee to speed decisions on the fate of the liquid biopsy test maker.

By Susan Kelly • Nov. 10, 2023

Acutus laying off 65% of employees to focus solely on Medtronic heart device deal

The company has decided to exit the mapping and ablation business and focus its remaining cash on the Medtronic partnership.

By Nick Paul Taylor • Nov. 10, 2023

4 takeaways from Stryker’s investor day

The company’s expected return to pre-pandemic operating margins, procedure backlogs and weight loss drugs were among the topics discussed at Wednesday’s event.

By Elise Reuter • Nov. 9, 2023

BD’s 2024 forecast comes in ‘well below’ Wall Street’s expectations

Wall Street analysts called out BD’s disappointing 2024 EPS forecast in notes to investors, following a Thursday morning earnings call.

By Ricky Zipp • Nov. 9, 2023

Masimo lowers outlook, citing constrained hospital budgets

The patient monitoring company is also facing a slowdown in demand for the consumer audio products it acquired in a deal last year.

By Susan Kelly • Nov. 8, 2023

Siemens Healthineers’ Varian rebounds; execs mum on diagnostics sale rumors

The company's diagnostics unit continued to struggle amid layoffs and reports of a potential sale.

By Nick Paul Taylor • Nov. 8, 2023

Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO

Tornos, who took the helm in August, said the company will grow through internal innovation and M&A.

By Elise Reuter • Nov. 7, 2023

Diabetes tech firms focusing on Type 2 patients

Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

By Elise Reuter • Nov. 7, 2023

5 companies to watch as medtech earnings wind down

Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

By Nick Paul Taylor • Nov. 6, 2023

Stryker in ‘sprint back to 2019’ as procedures grow and supply chain, staffing pressures improve

The company expects a procedure backlog to boost orthopedic surgery demand in the fourth quarter and through 2024.

By Ricky Zipp • Nov. 3, 2023